Detalhe da pesquisa
1.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med
; 388(1): 44-54, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546659
2.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658005
3.
Acquired Resistance to KRASG12C Inhibition in Cancer.
N Engl J Med
; 384(25): 2382-2393, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161704
4.
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Bioorg Med Chem
; 71: 116947, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35926325
5.
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Future Oncol
; 16(1): 4289-4301, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31778074
6.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Cancer
; 125(4): 533-540, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30570744
7.
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Cancer Immunol Immunother
; 67(3): 381-392, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29124315
8.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med
; 371(21): 1963-71, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25264305
9.
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
N Engl J Med
; 368(25): 2395-401, 2013 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724914
10.
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Xenobiotica
; 45(1): 45-59, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034009
11.
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
Genomics
; 102(3): 157-62, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23434628
12.
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Lung Cancer
; 190: 107512, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417277
13.
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Cancer Discov
; 14(2): 308-325, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931288
14.
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
J Med Chem
; 67(1): 774-781, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38156904
15.
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
J Med Chem
; 67(6): 4936-4949, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477582
16.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Mol Cancer Ther
; : OF1-OF13, 2024 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38904222
17.
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Science
; 384(6700): eadk0775, 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38843331
18.
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Cancer Cell
; 42(3): 413-428.e7, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402609
19.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Mol Cancer Ther
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641404
20.
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
N Engl J Med
; 363(18): 1727-33, 2010 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20979472